AnaptysBio Inc (NASDAQ:ANAB)’s share price reached a new 52-week high during trading on Thursday . The company traded as high as $88.37 and last traded at $81.95, with a volume of 185000 shares traded. The stock had previously closed at $84.72.
A number of equities analysts have commented on ANAB shares. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Tuesday, August 15th. Credit Suisse Group lifted their price objective on shares of AnaptysBio from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, August 25th. Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 target price on shares of AnaptysBio in a research note on Tuesday, September 12th. Royal Bank Of Canada started coverage on AnaptysBio in a research note on Thursday, September 14th. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, JMP Securities raised their target price on AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. AnaptysBio currently has a consensus rating of “Buy” and a consensus target price of $84.78.
The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Evercore Wealth Management LLC bought a new stake in AnaptysBio in the third quarter worth about $100,000. Legal & General Group Plc raised its position in AnaptysBio by 160.8% in the third quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock worth $110,000 after acquiring an additional 1,951 shares in the last quarter. Bank of America Corp DE bought a new stake in AnaptysBio in the first quarter worth about $123,000. DAFNA Capital Management LLC raised its position in AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 1,000 shares in the last quarter. Finally, New York State Common Retirement Fund purchased a new position in AnaptysBio in the 2nd quarter worth about $168,000. Institutional investors and hedge funds own 75.48% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/07/anaptysbio-anab-sets-new-1-year-high-at-88-37.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
What are top analysts saying about AnaptysBio Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AnaptysBio Inc and related companies.